TKNO: Teknova Company Total Sales

The risk of delayed profits due to cyclical demand in biotech is mitigated by Alpha Teknova, Inc. (TKNO) through exclusive R&D formulations and high automation of media filling. The company's sales volume dynamics demonstrate a key support zone, where the 0.05 mark serves as a relevant indicator. Business stability relies on the rapid creation of turnkey customized chemical compositions.

Alpha Teknova Inc (TKNO) - Company Sales from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for teknova.com (TKNO)

- market value and analyst target forecast:

Market Chart Teknova|TKNO - Consensus Target

- market capitalization information:

Market Value Alpha Teknova Inc|TKNO - Total Company Value

- book capitalization indicators:

Accounting Value of a Share Teknova|TKNO - Company Net Assets|Market Capitalization to Book Value Ratio teknova.com|TKNO - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

TKNO - Net Profit|Projected Future Earnings Alpha Teknova, Inc.|TKNO - Price to Earnings Ratio|Future Price to Earnings Alpha Teknova|TKNO - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Alpha Teknova, Inc.|TKNO - Operating profit EBITDA|Earnings per share for the trailing year Teknova|TKNO - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth teknova.com|TKNO - Net earnings per share growth this year|Expected earnings per share trend next year Alpha Teknova, Inc.

- issuer revenue and sales details:

TKNO - Company Sales|Company Projected Revenue Volume Alpha Teknova, Inc.|TKNO - P/S Multiple|Market Cap to Future Revenue Ratio Alpha Teknova Inc|TKNO - Sales Growth YoY (Last Twelve Months)

Comprehensive company analysis:Teknova TKNO

Signature product of Alpha Teknova, Inc.

By analyzing the trading revenue of Alpha Teknova, Inc. (TKNO), investors assess the issuer's status within the cell therapy sector. This indicator captures actual daily cash inflows from product sales, filtering out market noise. The metric's dynamics reflect demand sensitivity to the operational cycles of biotechnology clients. Growth in this figure confirms the effective scaling of liquid media production facilities, while a steady increase in inflows signals a recovery in business margins.

Competing companies